Upcoming Earnings: Q2 '26
Estimated EPS
-$0.25
Estimated Rev
$14.41M
• Reported GAAP EPS of -$0.13 up 66.67% YoY • Reported revenue of $14.31M up 39.53% YoY
Bullish Takeaway
Coherus Oncology achieved strong LOQTORZI revenue growth and patient demand during the second quarter while successfully advancing multiple next-generation oncology pipeline programs toward anticipated clinical data readouts in 2H 2026.
Bearish Takeaway
Coherus Oncology continues to report net losses from continuing operations, a significant decline in cash and marketable securities, and ongoing risks associated with clinical development and future capital funding requirements.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.25 | -- | -- | N/A |
Q1 '26 | -$0.26 | -$0.27 | -2.53% | MISSED |
Q4 '25 | -$0.36 | -$0.39 | -9.83% | MISSED |
Q3 '25 | -$0.35 | -$0.31 | 12.41% | BEAT |
Q2 '25 | -$0.22 | -$0.39 | -77.00% | MISSED |